A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality

Journal of Clinical Lipidology

Volumn 10, Issue 3, 2016, Pages 472-489

  Wadhera, Rishi K ^a   Steen, Dylan L ^b   Khan, Irfan ^c   Giugliano, Robert P ^a   Foody, Joanne M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c SANOFI   (France)

Author keywords

Cardiovascular disease; Epidemiology; Guidelines; LDL C; Lipid lowering therapy; Morbidity; Mortality; Risk

Indexed keywords

ALIROCUMAB; EVOLOCUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; EVIDENCE BASED PRACTICE; HEALTH CARE; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE MODIFICATION; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); MORBIDITY; MUSCULOSKELETAL DISEASE; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; CARDIOVASCULAR DISEASES; EVIDENCE BASED MEDICINE; LIFESTYLE; METABOLISM; MORTALITY; RISK;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; EVIDENCE-BASED MEDICINE; HUMANS; LIFE STYLE; RISK;

EID: 84969916584     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2015.11.010     Document Type: Review

References (158)

1. World Health Organization: Health statistics and information systems. Cause-specific mortality. Glob Summ estimates for 2000-2012. Available at: http://www.who.int/healthinfo/global-burden-disease/estimates/en/index1.html. Accessed January 2, 2015.
2. Epidemiology of Cardiovascular Disease Institute of Medicine (US) Committee on Preventing the Global Epidemic of Cardiovascular Disease: Meeting the Challenges in Developing Countries V. Fuster, and B.B. Kelly Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health 2010 National Academies Press (US) Washington (DC)
3. A.S. Go, D. Mozaffarian, V.L. Roger, and et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association Circulation 129 2014 e28 e292
4. C.J. Murray, and A.D. Lopez Measuring the global burden of disease N Engl J Med 369 2013 448 457
5. D.E. Bloom, E.T. Cafiero, E. Jane-Llopis, and et al. The Global Economic Burden of Noncommunicable Disease 2011 World Economic Forum Geneva
6. S. Yusuf, S. Hawken, S. Ounpuu, and et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 364 2004 937 952
7. L. Bjorck, A. Rosengren, K. Bennett, and et al. Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002 Eur Heart J 30 2009 1046 1056
8. P. Bandosz, M. O'Flaherty, W. Drygas, and et al. Decline in mortality from coronary heart disease in Poland after socioeconomic transformation: modelling study BMJ 344 2012 d8136
9. H.C. Wijeysundera, M. Machado, F. Farahati, and et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005 JAMA 303 2010 1841 1847
10. G. Flores-Mateo, M. Grau, M. O'Flaherty, and et al. [Analyzing the coronary heart disease mortality decline in a Mediterranean population: Spain 1988-2005] Rev Esp Cardiol 64 2011 988 996
11. J. Hughes, F. Kee, M. O'Flaherty, and et al. Modelling coronary heart disease mortality in Northern Ireland between 1987 and 2007: broader lessons for prevention Eur J Prev Cardiol 20 2013 310 321
12. E.S. Ford, U.A. Ajani, J.B. Croft, and et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000 N Engl J Med 356 2007 2388 2398
13. T. Aspelund, V. Gudnason, B.T. Magnusdottir, and et al. Analysing the large decline in coronary heart disease mortality in the Icelandic population aged 25-74 between the years 1981 and 2006 PLoS One 5 2010 e13957
14. L. Palmieri, K. Bennett, S. Giampaoli, and et al. Explaining the decrease in coronary heart disease mortality in Italy between 1980 and 2000 Am J Public Health 100 2010 684 692
15. J.W. Hotchkiss, C.A. Davies, R. Dundas, and et al. Explaining trends in Scottish coronary heart disease mortality between 2000 and 2010 using IMPACTSEC model: retrospective analysis using routine data BMJ 348 2014 g1088
16. M. Bajekal, S. Scholes, H. Love, and et al. Analysing recent socioeconomic trends in coronary heart disease mortality in England, 2000-2007: a population modelling study PLoS Med 9 2012 e1001237
17. N.J. Stone, J.G. Robinson, A.H. Lichtenstein, and et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 129 2014 S1 45
18. Task Force for the management of dyslipidaemias of the European Society of Cardiology, European Atherosclerosis Society A.L. Catapano, Z. Reiner, G. De Backer, and et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Atherosclerosis 217 Suppl 1 2011 S1 S44
19. T.A. Jacobson, M.K. Ito, K.C. Maki, and et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1-executive summary J Clin Lipidol 8 2014 473 488
20. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel Members An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia-full report J Clin Lipidol 8 2014 29 60
21. Feingold KR, Grunfeld C: Introduction to Lipids and Lipoproteins. In: De Groot LJ, Beck-Peccoz P, Chrousos G, et al, eds. Endotext. South Dartmouth (MA), 2000.
22. R. Ross Atherosclerosis is an inflammatory disease Am Heart J 138 1999 S419 S420
23. M.M. Veniant, M.A. Sullivan, S.K. Kim, and et al. Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100 J Clin Invest 106 2000 1501 1510
24. H.D. Lieu, S.K. Withycombe, Q. Walker, and et al. Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion Circulation 107 2003 1315 1321
25. P.W. Wilson, R.B. D'Agostino, D. Levy, and et al. Prediction of coronary heart disease using risk factor categories Circulation 97 1998 1837 1847
26. A.R. Sharrett, C.M. Ballantyne, S.A. Coady, and et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study Circulation 104 2001 1108 1113
27. C.J. Willer, S. Sanna, A.U. Jackson, and et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease Nat Genet 40 2008 161 169
28. S. Kathiresan, O. Melander, D. Anevski, and et al. Polymorphisms associated with cholesterol and risk of cardiovascular events N Engl J Med 358 2008 1240 1249
29. The Myocardial Infarction Genetics Consortium Investigators N.O. Stitziel, H.H. Won, A.C. Morrison, and et al. Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease N Engl J Med 371 2014 2072 2082
30. P. Linsel-Nitschke, A. Gotz, J. Erdmann, and et al. Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease-a Mendelian Randomisation study PLoS One 3 2008 e2986
31. S. Stender, R. Frikke-Schmidt, B.G. Nordestgaard, and et al. The ABCG5/8 cholesterol transporter and myocardial infarction versus gallstone disease J Am Coll Cardiol 63 2014 2121 2128
32. TG HDL Working Group of the Exome Sequencing Project National Heart Lung and Blood Institute J. Crosby, G.M. Peloso, P.L. Auer, and et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease N Engl J Med 371 2014 22 31
33. J.C. Cohen, E. Boerwinkle, T.H. Mosley Jr., and et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
34. B.A. Ference, W. Yoo, I. Alesh, and et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis J Am Coll Cardiol 60 2012 2631 2639
35. Cholesterol Treatment Trialists Collaborators B. Mihaylova, J. Emberson, L. Blackwell, and et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590
36. D. Steinberg, and J.L. Witztum Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels Proc Natl Acad Sci U S A 106 2009 9546 9547
37. A.M. Navar-Boggan, E.D. Peterson, R.B. D'Agostino Sr., and et al. Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease Circulation 131 2015 451 458
38. J.D. Otvos, S. Mora, I. Shalaurova, and et al. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number J Clin Lipidol 5 2011 105 113
39. I. Tabas, K.J. Williams, and J. Boren Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications Circulation 116 2007 1832 1844
40. K.K. Berneis, and R.M. Krauss Metabolic origins and clinical significance of LDL heterogeneity J Lipid Res 43 2002 1363 1379
41. A.D. Sniderman, K. Williams, J.H. Contois, and et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk Circ Cardiovasc Qual Outcomes 4 2011 337 345
42. S.M. Boekholdt, B.J. Arsenault, S. Mora, and et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis JAMA 307 2012 1302 1309
43. J.H. O'Keefe Jr., and L. Cordain Cardiovascular disease resulting from a diet and lifestyle at odds with our Paleolithic genome: how to become a 21st-century hunter-gatherer Mayo Clin Proc 79 2004 101 108
44. L. Cordain, S.B. Eaton, J.B. Miller, and et al. The paradoxical nature of hunter-gatherer diets: meat-based, yet non-atherogenic Eur J Clin Nutr 56 Suppl 1 2002 S42 S52
45. J.H. O'Keefe Jr., L. Cordain, W.H. Harris, and et al. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal J Am Coll Cardiol 43 2004 2142 2146
46. P. Puska From Framingham to North Karelia: from descriptive epidemiology to public health action Prog Cardiovasc Dis 53 2010 15 20
47. E. Vartiainen, T. Laatikainen, M. Peltonen, and et al. Thirty-five-year trends in cardiovascular risk factors in Finland Int J Epidemiol 39 2010 504 518
48. L. Brown, B. Rosner, W.W. Willett, and et al. Cholesterol-lowering effects of dietary fiber: a meta-analysis Am J Clin Nutr 69 1999 30 42
49. I. Demonty, R.T. Ras, H.C. van der Knaap, and et al. Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phytosterol intake J Nutr 139 2009 271 284
50. J. Sabate, K. Oda, and E. Ros Nut consumption and blood lipid levels: a pooled analysis of 25 intervention trials Arch Intern Med 170 2010 821 827
51. K. Taku, K. Umegaki, Y. Sato, and et al. Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials Am J Clin Nutr 85 2007 1148 1156
52. P.T. Williams, R.M. Krauss, S. Kindel-Joyce, and et al. Relationship of dietary fat, protein, cholesterol, and fiber intake to atherogenic lipoproteins in men Am J Clin Nutr 44 1986 788 797
53. P.W. Siri, and R.M. Krauss Influence of dietary carbohydrate and fat on LDL and HDL particle distributions Curr Atheroscler Rep 7 2005 455 459
54. D. Mozaffarian, A. Aro, and W.C. Willett Health effects of trans-fatty acids: experimental and observational evidence Eur J Clin Nutr 63 Suppl 2 2009 S5 S21
55. C. Richard, P. Couture, S. Desroches, and et al. Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome Br J Nutr 107 2012 705 711
56. E.N. Georgousopoulou, C. Pitsavos, D. Panagiotakos, and et al. Adherence to Mediterranean is the most important protector against the development of fatal and non-fatal cardiovascular event: 10-year follow-up (2002-12) of the Attica study J Am Coll Cardiol 65 2015 A1449
57. D. Ornish, S.E. Brown, L.W. Scherwitz, and et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial Lancet 336 1990 129 133
58. R. Belardinelli, I. Paolini, G. Cianci, and et al. Exercise training intervention after coronary angioplasty: the ETICA trial J Am Coll Cardiol 37 2001 1891 1900
59. D. Wosornu, D. Bedford, and D. Ballantyne A comparison of the effects of strength and aerobic exercise training on exercise capacity and lipids after coronary artery bypass surgery Eur Heart J 17 1996 854 863
60. C.M. Yu, L.S. Li, H.H. Ho, and et al. Long-term changes in exercise capacity, quality of life, body anthropometry, and lipid profiles after a cardiac rehabilitation program in obese patients with coronary heart disease Am J Cardiol 91 2003 321 325
61. P.D. Wood, M.L. Stefanick, D.M. Dreon, and et al. Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise N Engl J Med 319 1988 1173 1179
62. M. Halle, A. Berg, D. Konig, and et al. Differences in the concentration and composition of low-density lipoprotein subfraction particles between sedentary and trained hypercholesterolemic men Metabolism 46 1997 186 191
63. P.T. Williams, R.M. Krauss, K.M. Vranizan, and et al. Effects of exercise-induced weight loss on low density lipoprotein subfractions in healthy men Arteriosclerosis 9 1989 623 632
64. W.E. Kraus, J.A. Houmard, B.D. Duscha, and et al. Effects of the amount and intensity of exercise on plasma lipoproteins N Engl J Med 347 2002 1483 1492
65. H.M. Ahmed, M.J. Blaha, K. Nasir, and et al. Effects of physical activity on cardiovascular disease Am J Cardiol 109 2012 288 295
66. B.M. Scirica, and C.P. Cannon Treatment of elevated cholesterol Circulation 111 2005 e360 e363
67. The Lipid Research Clinics Coronary Primary Prevention Trial results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering JAMA 251 1984 365 374
68. P.L. Canner, K.G. Berge, N.K. Wenger, and et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin J Am Coll Cardiol 8 1986 1245 1255
69. HPS2-THRIVE Collaborative Group M.J. Landray, R. Haynes, J.C. Hopewell, and et al. Effects of extended-release niacin with laropiprant in high-risk patients N Engl J Med 371 2014 203 212
70. AIM-HIGH Investigators W.E. Boden, J.L. Probstfield, T. Anderson, and et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
71. S.W. Altmann, H.R. Davis Jr., L.J. Zhu, and et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption Science 303 2004 1201 1204
72. T. Sudhop, D. Lutjohann, A. Kodal, and et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans Circulation 106 2002 1943 1948
73. C.P. Cannon, M.A. Blazing, R.P. Giugliano, and et al. Ezetimibe added to statin therapy after acute coronary syndromes N Engl J Med 372 2015 2387 2397
74. J. Shepherd, S.M. Cobbe, I. Ford, and et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med 333 1995 1301 1307
75. J.R. Downs, M. Clearfield, S. Weis, and et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
76. J. Shepherd, G.J. Blauw, M.B. Murphy, and et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630
77. ALLHAT Officers and Coordinators for the Allhat Collaborative Research Group, The Antihypertensive Lipid-Lowering Treatment to Prevent Heart Attack Trial Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) JAMA 288 2002 2998 3007
78. P.S. Sever, B. Dahlof, N.R. Poulter, and et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158
79. H.M. Colhoun, D.J. Betteridge, P.N. Durrington, and et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
80. R.H. Knopp, M. d'Emden, J.G. Smilde, and et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN) Diabetes Care 29 2006 1478 1485
81. H. Nakamura, K. Arakawa, H. Itakura, and et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial Lancet 368 2006 1155 1163
82. P.M. Ridker, E. Danielson, F.A. Fonseca, and et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
83. T.R. Pedersen, A.G. Olsson, O. Faergeman, and et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) Circulation 97 1998 1453 1460
84. F.M. Sacks, M.A. Pfeffer, L.A. Moye, and et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N Engl J Med 335 1996 1001 1009
85. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
86. P.W. Serruys, P. de Feyter, C. Macaya, and et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial JAMA 287 2002 3215 3222
87. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
88. M.J. Koren, and D.B. Hunninghake ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study J Am Coll Cardiol 44 2004 1772 1779
89. C.P. Cannon, E. Braunwald, C.H. McCabe, and et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
90. J.A. de Lemos, M.A. Blazing, S.D. Wiviott, and et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA 292 2004 1307 1316
91. J.C. LaRosa, S.M. Grundy, D.D. Waters, and et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
92. T.R. Pedersen, O. Faergeman, J.J. Kastelein, and et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445
93. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine Collaborative Group J. Armitage, L. Bowman, K. Wallendszus, and et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial Lancet 376 2010 1658 1669
94. Cholesterol Treatment Trialists Collaboration C. Baigent, L. Blackwell, J. Emberson, and et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
95. Cholesterol Treatment Trialists Collaboration J. Fulcher, R. O'Connell, M. Voysey, and et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials Lancet 385 2015 1397 1405
96. P. Maningat, and J.L. Breslow Needed: pragmatic clinical trials for statin-intolerant patients N Engl J Med 365 2011 2250 2251
97. A. Kashani, C.O. Phillips, J.M. Foody, and et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials Circulation 114 2006 2788 2797
98. Cholesterol Treatment Trialists Collaboration J.R. Emberson, P.M. Kearney, L. Blackwell, and et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy PLoS One 7 2012 e29849
99. D. Preiss, S.R. Seshasai, P. Welsh, and et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 2011 2556 2564
100. N. Sattar, D. Preiss, H.M. Murray, and et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
101. P.M. Ridker, A. Pradhan, J.G. MacFadyen, and et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial Lancet 380 2012 565 571
102. R.M. Conroy, K. Pyorala, A.P. Fitzgerald, and et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project Eur Heart J 24 2003 987 1003
103. M.S. Abdallah, M. Kosiborod, F. Tang, and et al. Patterns and predictors of intensive statin therapy among patients with diabetes mellitus after acute myocardial infarction Am J Cardiol 113 2014 1267 1272
104. S.V. Arnold, M. Kosiborod, F. Tang, and et al. Patterns of statin initiation, intensification, and maximization among patients hospitalized with an acute myocardial infarction Circulation 129 2014 1303 1309
105. U. Javed, P.C. Deedwania, D.L. Bhatt, and et al. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospita participating in Get With The Guidelines (GWTG) Am Heart J 161 2011 418 424.e1-3
106. B. McGinnis, K.L. Olson, D. Magid, and et al. Factors related to adherence to statin therapy Ann Pharmacother 41 2007 1805 1811
107. M.J. Pencina, A.M. Navar-Boggan, R.B. D'Agostino Sr., and et al. Application of new cholesterol guidelines to a population-based sample N Engl J Med 370 2014 1422 1431
108. National Cholesterol Education Program Expert (NCEP) Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
109. K.K. Ray, J.J. Kastelein, S.M. Boekholdt, and et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011 Eur Heart J 35 2014 960 968
110. A. Pandya, S. Sy, S. Cho, and et al. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease JAMA 314 2015 142 150
111. S.M. Boekholdt, G.K. Hovingh, S. Mora, and et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials J Am Coll Cardiol 64 2014 485 494
112. J. Hsia, J.G. MacFadyen, J. Monyak, and et al. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) J Am Coll Cardiol 57 2011 1666 1675
113. S.D. Wiviott, C.P. Cannon, D.A. Morrow, and et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy J Am Coll Cardiol 46 2005 1411 1416
114. B.M. Everett, S. Mora, R.J. Glynn, and et al. Safety Profile of Subjects Treated to Very Low Low-Density Lipoprotein Cholesterol Levels (<30 mg/dl) With Rosuvastatin 20 mg Daily (from JUPITER) Am J Cardiol 114 2014 1682 1689
115. H. Nagasaka, H. Chiba, H. Kikuta, and et al. Unique character and metabolism of high density lipoprotein (HDL) in fetus Atherosclerosis 161 2002 215 223
116. M.R. Averna, C.M. Barbagallo, G. Di Paola, and et al. Lipids, lipoproteins and apolipoproteins AI, AII, B, CII, CIII and E in newborns Biol Neonate 60 1991 187 192
117. D. Steinberg, C.K. Glass, and J.L. Witztum Evidence mandating earlier and more aggressive treatment of hypercholesterolemia Circulation 118 2008 672 677
118. A.J. Hooper, A.D. Marais, D.M. Tanyanyiwa, and J.R. Burnett The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population Atherosclerosis 193 2007 445 448
119. Z. Zhao, Y. Tuakli-Wosornu, T.A. Lagace, and et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote Am J Hum Genet 79 2006 514 523
120. J.C. Cohen Emerging LDL therapies: Using human genetics to discover new therapeutic targets for plasma lipids J Clin Lipidol 7 2013 S1 S5
121. D. Urban, J. Poss, M. Bohm, and et al. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis J Am Coll Cardiol 62 2013 1401 1408
122. L. Joseph, and J.G. Robinson Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy Prog Cardiovasc Dis 58 2015 19 31
123. J.G. Robinson, M. Farnier, M. Krempf, and et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events N Engl J Med 372 2015 1489 1499
124. G.G. Schwartz, L. Bessac, L.G. Berdan, and et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial Am Heart J 168 2014 682 689.e1
125. M.S. Sabatine, R.P. Giugliano, S.D. Wiviott, and et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events N Engl J Med 372 2015 1500 1509
126. N.R. Desai, and M.S. Sabatine PCSK9 inhibition in patients with hypercholesterolemia Trends Cardiovasc Med 25 2015 567 574
127. E.P. Navarese, M. Kolodziejczak, V. Schulze, and et al. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis Ann Intern Med 163 2015 40 51
128. P.J. Barter, M. Caulfield, M. Eriksson, and et al. Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
129. A.H. Mohammadpour, and F. Akhlaghi Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective Clin Pharmacokinet 52 2013 615 626
130. G.G. Schwartz, A.G. Olsson, M. Abt, and et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
131. Lilly to Discontinue Development of Evacetrapib for High-Risk Atherosclerotic Cardiovascular Disease, 2015. Available at: https://investor.lilly.com/releasedetail.cfm?ReleaseID=936130.
132. C.P. Cannon, S. Shah, H.M. Dansky, and et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2010 2406 2415
133. R.M. Krauss, C.A. Pinto, Y. Liu, and et al. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin J Clin Lipidol 9 2015 93 102
134. M.L. O'Donoghue, E. Braunwald, H.D. White, and et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial JAMA 312 2014 1006 1015
135. J. Cespedes, G. Briceno, M.E. Farkouh, and et al. Targeting preschool children to promote cardiovascular health: cluster randomized trial Am J Med 126 2013 27 35.e3
136. D.K. Arnett, D.R. Jacobs Jr., R.V. Luepker, and et al. Twenty-year trends in serum cholesterol, hypercholesterolemia, and cholesterol medication use: the Minnesota Heart Survey, 1980-1982 to 2000-2002 Circulation 112 2005 3884 3891
137. Centers for Disease Control and Prevention Disparities in screening for and awareness of high blood cholesterol-United States, 1999-2002 MMWR Morb Mortal Wkly Rep 54 2005 117 119
138. S.V. Arnold, J.A. Spertus, F.A. Masoudi, and et al. Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction J Am Coll Cardiol 62 2013 1791 1801
139. N.K. Choudhry, R.J. Glynn, J. Avorn, and et al. Untangling the relationship between medication adherence and post-myocardial infarction outcomes: medication adherence and clinical outcomes Am Heart J 167 2014 51 58.e5
140. J.S. Benner, R.J. Glynn, H. Mogun, and et al. Long-term persistence in use of statin therapy in elderly patients JAMA 288 2002 455 461
141. D.M. Mann, M. Woodward, P. Muntner, and et al. Predictors of nonadherence to statins: a systematic review and meta-analysis Ann Pharmacother 44 2010 1410 1421
142. D.N. Kiortsis, P. Giral, E. Bruckert, and et al. Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients J Clin Pharm Ther 25 2000 445 451
143. B. Kopjar, A.E. Sales, S.L. Pineros, and et al. Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population Am J Cardiol 92 2003 1106 1108
144. W. Insull The problem of compliance to cholesterol altering therapy J Intern Med 241 1997 317 325
145. C.A. Jackevicius, M. Mamdani, and J.V. Tu Adherence with statin therapy in elderly patients with and without acute coronary syndromes JAMA 288 2002 462 467
146. N. Col, J.E. Fanale, and P. Kronholm The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly Arch Intern Med 150 1990 841 845
147. C.S. Stilley, S. Sereika, M.F. Muldoon, and et al. Psychological and cognitive function: predictors of adherence with cholesterol lowering treatment Ann Behav Med 27 2004 117 124
148. J. Avorn, J. Monette, A. Lacour, and et al. Persistence of use of lipid-lowering medications: a cross-national study JAMA 279 1998 1458 1462
149. T.B. Gibson, T.L. Mark, K.A. McGuigan, and et al. The effects of prescription drug copayments on statin adherence Am J Manag Care 12 2006 509 517
150. J.D. Cohen, E.A. Brinton, M.K. Ito, and et al. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users J Clin Lipidol 6 2012 208 215
151. P. Maningat, B.R. Gordon, and J.L. Breslow How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep 15 2013 291
152. M.B. Yilmaz, M. Pinar, I. Naharci, and et al. Being well-informed about statin is associated with continuous adherence and reaching targets Cardiovasc Drugs Ther 19 2005 437 440
153. A. Schedlbauer, P. Davies, and T. Fahey Interventions to improve adherence to lipid lowering medication Cochrane Database Syst Rev 2010 CD004371
154. P. Muntner, D. Mann, R.P. Wildman, and et al. Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects Am Heart J 161 2011 719 725
155. H. Zhang, J. Plutzky, S. Skentzos, and et al. Discontinuation of statins in routine care settings: a cohort study Ann Intern Med 158 2013 526 534
156. M. Reed, J. Huang, I. Graetz, and et al. Outpatient electronic health records and the clinical care and outcomes of patients with diabetes mellitus Ann Intern Med 157 2012 482 489
157. K. Levin, J.R. Madsen, I. Petersen, and et al. Telemedicine diabetes consultations are cost-effective, and effects on essential diabetes treatment parameters are similar to conventional treatment: 7-year results from the Svendborg Telemedicine Diabetes Project J Diabetes Sci Technol 7 2013 587 595
158. K.E. Aspry, R. Furman, D.G. Karalis, and et al. Effect of health information technology interventions on lipid management in clinical practice: a systematic review of randomized controlled trials J Clin Lipidol 7 2013 546 560